Abdomino-pelvic computed tomography in the management of ovarian carcinoma

The Potential Value of CA125 as a Tumour Marker in Small Volume, Non-Evaluable Epithelial Ovarian Cancer

Seventy four consecutive patients with epithelial ovarian cancer have been followed up longitudinally with serial serum CA125 for up to 48 months. From this database, the CAl25 changes in small volume disease have been evaluated.

For long term complete responders (n = l2), the mean plateau level of CA125 was 7.2 U/ml (95% confidence interval; 5.6 to 9.2 U/ml). The natural half-life of CA125 at 5.1 days (range 3.8 to 7 days) was calculated from five patients with Stage I and II disease who underwent complete surgical excision. A mean lead time of 99 days (range 14 to 255 days) was demonstrated between marker detection of disease progression and clinically apparent progressive disease in 12 out of 13 patients (92%) who relapsed after chemotherapy induced complete remission. The threshold of tumour volume detection with CA125 is unlikely to be determined by an arbitrary cut-off level. The kinetics of CA125 provide more useful information and the potential to define complete response or indeed cure with CA125 parameters requires further investigation.

Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment

Ovarian epithelial carcinoma (OEC), the most common ovarian malignancy, is a heterogeneous disease with several histologic subtypes that show characteristic cytogenetic features, molecular signatures, oncologic signaling pathways, and clinical-biologic behavior. Recent advances in histopathology and cytogenetics have provided insights into pathophysiologic features and natural history of OECs. Several studies have shown that high- or low-grade serous, endometrioid, and clear cell carcinomas are characterized by mutations involving the TP53, K-ras/BRAF, CTNNB1, and PIK3CA genes, respectively. High-grade serous carcinomas, the most common subtype, often manifest with early transcoelomic spread of disease beyond the ovaries, whereas low-grade serous and mucinous carcinomas commonly manifest with early-stage disease, with a resultant excellent prognosis. On the basis of pathogenetic mechanisms, recent findings suggest a dualistic model of ovarian carcinogenesis consisting of types I and II. Type I (low-grade serous, mucinous, and endometrioid) cancers commonly arise from well-described, genetically stable precursor lesions (usually borderline tumors); manifest as large adnexal masses with early-stage disease; and have a relatively indolent clinical course, with an overall good prognosis. In contrast, type II carcinomas (high-grade serous, endometrioid, mixed, and undifferentiated variants) originate de novo from the adnexal epithelia, often demonstrate chromosomal instability, and have aggressive biologic behavior. Better knowledge of hereditary ovarian cancer syndromes and associated cytogenetic abnormalities has led to increased interest in novel biomarkers and molecular therapeutics. Genetic changes, pathologic features, imaging findings, and natural histories of a variety of histologic subtypes of OEC are discussed in this article.

The utility of multi-detector computed tomography in the diagnosis of malignant pleural effusion in the patients with ovarian cancer

PURPOSE

The purpose of this study was to retrospectively assess possible clinical predictors of malignant pleural effusion in patients with ovarian cancer.

MATERIALS AND METHODS

This review was performed on 38 ovarian cancer patients that showed pleural effusion in a CT scan and who underwent thoracocentesis before treatment. CT scans were obtained using a 4-channel multi-detector CT scanner. Fisher's exact test was used to determine the probability of malignant pleural effusion as a function of; amount of ascites, lymph node enlargement, amount of pleural effusion, pleural nodules, and pleural thickening.

RESULTS

Sixteen (42.1%) of the 38 patients had malignant pleural effusion and malignant pleural effusion amounts were greater than those with nonmalignant effusion. Pleural nodules were more frequently found in the malignant pleural effusion group (eight [50%] patients) than in the nonmalignant group (zero [0%] patient) (p<0.001). Supradiaphragmatic lymph node enlargement (with short axis diameter 1cm or more) was more frequent in malignant group (12 [75%] patients) than in the nonmalignant group (two [9.1%] patients) (p<0.001).

CONCLUSION

The probability of malignant pleural effusion in patients with ovarian cancer was found to be correlated with the amount of pleural effusion, the presence of pleural nodules, and supradiaphragmatic lymph node enlargement.

Sonographic findings in women with complications after hysterectomy

OBJECTIVE

To study the role of abdominal ultrasound in the management of complications after emergency or elective hysterectomy.

METHODOLOGY

The study compared 102 women who had complications after emergency peripartum hysterectomy (study group) with 102 women who had complications after elective hysterectomy for fibroids (control group).

RESULTS

The study group had a lower mean age (31.1+/-2.1 vs 40.1+/-3.4 years) but higher parity (3.0+/-1.3 vs 2.0+/-1.2) compared with the control group. The primary complication in the study group was abdominal mass or distension (55.9%) compared with chronic abdominal pain (49.0%) in the control group. The leading sonographic abnormality in the study group was pelvic abscess (9.8%) while hydrosalpinx (6.9%) was more common in the control group. There was no statistical difference in the findings between the groups. Management of complications included ovarian cystectomy and drainage of pelvic abscesses.

CONCLUSION

Ultrasound facilitates accurate diagnosis of complications after hysterectomy and enhances management.

MR imaging in ovarian cancer

Magnetic resonance (MR) imaging is increasingly being used in patients with gynaecological disorders due to its high contrast resolution compared to computed tomography (CT) and ultrasound. In women presenting with an adnexal mass, ultrasound remains the primary imaging modality in the detection and characterisation of such lesions. However, in recent years overwhelming evidence has accumulated for the use of MR imaging in patients with indeterminate adnexal masses particularly in younger women and where disease markers are unhelpful. In staging ovarian cancer and for evaluating therapeutic response MR imaging is as accurate as CT but CT remains the imaging modality of choice because it is more widely available and quicker. This article reviews that evidence and outlines a place for the use of MR imaging in ovarian cancer.

ACR Appropriateness Criteria® on Staging and Follow-Up of Ovarian Cancer

Ovarian cancer is the most common cause of cancer death from gynecologic malignancy in women. The diagnosis and treatment of ovarian cancer are especially challenging because of the high prevalence of benign disease in the ovaries and the tendency for late presentation of ovarian cancer after it has spread. The role of diagnostic imaging is in lesion detection, lesion characterization, preoperative staging, and the prediction of disease resectability that may require chemotherapy and later debulking for improved survival.

Role of chest CT in the follow-up of ovarian adenocarcinoma

OBJECTIVE

We describe the prevalence of metastatic chest disease in ovarian adenocarcinoma as seen on CT. We sought to determine whether routine chest CT added any pertinent information to the follow-up examination of patients with ovarian adenocarcinoma.

MATERIALS AND METHODS

Retrospective review of our tumor registry yielded 96 patients with ovarian adenocarcinoma who had only a single primary malignancy and at least one CT scan of the chest, abdomen, and pelvis. CT scans were reviewed to assess the presence of metastatic chest disease in relation to disease activity in the abdomen and pelvis. Chest CT findings were correlated with the physical examination findings and CA-125 levels and were reviewed in consultation with a gynecologic oncologist to select only those patients with chest abnormalities attributable to metastatic disease.

RESULTS

A total of 266 CT scans were obtained. Forty (41.7%) of the 96 patients had abnormalities attributable to metastatic chest disease on one or more scans. In the absence of disease progression in the abdomen and pelvis, chest disease progression was seen in only six (2.7%) of the 226 follow-up CT scans. Five of the six patients had rising CA-125 levels.

CONCLUSION

Correlation of the findings of abdominal and pelvic CT with the physical findings and the CA-125 levels serves as effective follow-up in patients with ovarian adenocarcinoma. The contribution of additional chest CT in these patients is small.

Imaging of ovarian cancer

Cross sectional imaging continues to play an increasingly important role in ovarian cancer diagnosis, staging, and treatment follow-up. Screening for ovarian cancer remains a controversial subject. The combined use of clinical examination, CA-125, and endovaginal ultrasound (US) are being advocated for high risk patients but consensus recommendation for screening awaits further studies. In characterization of an ovarian neoplasm US is indisputedly the primary imaging approach. Only when US is inconclusive are further studies warranted. Magnetic resonance imaging (MRI) is generally preferred to computer tomography (CT). A prospective MRI-CT clinical trial has not been performed as yet. Preoperative staging by imaging is slowly gaining its acceptance. This is mostly due to the awareness of the difficulties and inaccuracy in surgical staging when unsuspected extensive disease is present. Furthermore, in known resectable ovarian cancer, primary chemotherapeutic cytoreduction may be a better treatment option. Accuracy of CT and MRI in staging ovarian cancer is similar, CT, however, is faster, more widely available, and less expensive; these are important attributes that are decisive in this time of health reimbursement constraints.

CT and MRI of ovarian cancer

Among the gynecologic malignancies, ovarian cancer is second most common in incidence. However, unlike the other gynecologic cancers, its mortality has decreased only minimally during the last two decades [1]. Only recently, preliminary studies suggest promising results for ovarian cancer screening using transvaginal ultrasound in combination with serum Ca 125 levels [22,23]. Exploratory laparotomy has been the mainstay in the management of ovarian cancer, as it offers histopathological evaluation as well as cytoreduction. However, it is limited by its inaccuracy with understaging in 30-40% at initial presentation. Cross-sectional imaging contributes valuable information toward preoperative surgical and management planning. The proper surgical approach can be selected, the need for preoperative chemotherapeutic debulking can be assessed, and the surgeon will be forewarned of the need for assistance from a gynecologic oncologic surgeon or gastrointestinal oncologic surgeon if a complicated surgical procedure or bowel resection is indicated. CT is established as the primary imaging modality for characterization of ovarian tumors and ovarian cancer staging, while MR is emerging as a problem-solving modality. MR seems to be superior to CT in lesion characterization, in evaluation of local extent of tumor, and in tumor implants involving the hemidiaphragm and liver surface. The role of spiral CT has yet to be explored.

Primary ovarian cancer: prospective comparison of contrast-enhanced CT and pre-and postcontrast, fat-suppressed MR imaging, with histologic correlation

Sixteen patients with clinically suspected malignant ovarian disease underwent contrast agent-enhanced computed tomography (CT) and magnetic resonance (MR) imaging in a prospective comparative study. MR imaging included fat-suppressed spin-echo and breath-hold FLASH (fast low-angle shot) before and after intravenous injection of gadopentetate dimeglumine. Histologic confirmation was obtained at laparotomy (n = 13) and biopsy (n = 3). Thirteen patients had histologically proven primary ovarian cancer. MR images showed the internal architecture of ovarian tumors better than CT in nine patients and equivalently in seven. MR images showed the relationship between ovarian tumors and adjacent pelvic structures (uterus [n = 9], sigmoid colon [n = 7], bladder [n = 7], and rectum [n = 3]) better than CT in nine patients and equivalently in seven. Intraabdominal extent of disease was better defined on MR than on CT images in nine patients, equivalently in six, and worse in one. Peritoneal metastases 1-2 cm in diameter were detected on MR images and missed on CT scans in six patients. In only one case did this result in a staging error with CT. The results suggest that MR imaging is at least equivalent and may be superior to CT in the evaluation of ovarian malignancy.

CA125-response assessment in epithelial ovarian cancer

To assess the clinical potential of serial serum CA125 measurements in the follow-up of patients with epithelial ovarian cancer, 74 consecutive unselected patients with histologically confirmed ovarian carcinoma were studied prospectively. There was an 83% concordance between clinical assessment and CA125 assessment of response. The positive predictive values of a rising CA125 for disease progression and a falling CA125 for disease regression were 0.93 and 0.94, respectively. The absolute CA125 values during observations of complete response (mean 96 U/ml; 95% confidence interval; 33 to 128 U/ml), partial response (mean 134 U/ml; 95% confidence interval; 98 to 159 U/ml) and stable or progressive disease (mean 391 U/ml; 95% confidence interval; 282 to 545 U/ml) were significantly different. A randomized study is required to determine whether CA125 monitoring has any benefit in terms of outcome, and particularly survival, in epithelial ovarian cancer.

Applications of computed tomography in gynecologic diseases

Computed tomography (CT) has evolved to play a significant role in the assessment of gynecologic diseases, primarily gynecologic malignancies. The cross-sectional display provides clear depiction of the female pelvic organs, viscera, and their surrounding fat planes. In the evaluation of certain pelvic malignancies, CT has become a fundamental study in the initial staging and subsequent follow-up of patients undergoing chemotherapy and radiation treatment. This manuscript describes and illustrates the role of CT in evaluating a spectrum of gynecologic pathology.

Diagnostic imaging of gynecological diseases: the clinician's view

The introduction of ultrasonography, computerized tomography, and magnetic resonance imaging has led to tremendous progress in the diagnostic evaluation of gynecologic diseases. Refinements in these techniques have allowed the gynecologist to diagnose unsuspected pathology, define disease and its extent, and select the most appropriate treatment despite limitations in specificity experience and cost. Practically the most appropriate imaging modalities are: ultrasonography for adnexal masses, computerized tomography for advanced cervical cancers, and magnetic resonance imaging for corpus cancers and selected cervical cancers.

Advances in gynecologic imaging and intervention

Advances in diagnostic imaging of the female genital tract facilitate characterization of many pelvic masses. Preoperative assessment of gynecologic malignant tumors provides information that may alter the surgical approach or timing of radiation therapy. Image-guided biopsy accurately confirms recurrent malignant lesions. Transcervical techniques have improved diagnostic assessment of infertile couples; thus, effective and inexpensive treatment options can be offered. Postoperative complications of gynecologic procedures can be detected with imaging, and many can be treated with image-guided techniques.

Monitoring patients with ovarian carcinoma: the relationship of serum CA125 levels to CT scanning

The serial levels of the serum tumor marker CA125 were compared with the results of concurrent abdominopelvic CT scans throughout the clinical course of 65 patients undergoing treatment for advanced epithelial ovarian carcinoma at this institution. Twenty-three of these patients subsequently underwent a second laparotomy following chemotherapy, and the pathological findings were correlated with the preoperative results of both the serum CA125 levels and CT scan appearances in order to establish the relative accuracies of the two tests in the diagnosis of residual disease. Initially, all patients had an elevated CA125 level (< 400 units ml-1) which fell to normal following treatment in all cases. Seventy-five percent of patients showed continuing evidence of disease on CT grounds when both clinical examination and serum CA125 levels had normalized during or following treatment. Patients whose maximum response was PR on CT criteria relapsed faster than those achieving CR, showing CT to be a useful indicator of residual disease when the CA125 level has normalized after chemotherapy. Comparing the CT results and CA125 levels after second-look surgery in 23 patients showed CT to have a sensitivity of 85% and specificity of 42%; CA125 had a sensitivity of 50% with a specificity of 100%. Using this data, a protocol for monitoring patients undergoing treatment and follow-up for ovarian carcinoma is suggested.

OC125 immunoscintigraphy in ovarian carcinoma: a comparison with alternative methods of assessment

The membrane bound, tumour associated antigen CA125 is recognized by the monoclonal antibody OC125 and may be detected in tumour tissue and serum in over 80% of patients with epithelial ovarian carcinomas. A total of 13 immunoscintigrams using 111 MBq 131I-OC125 have been performed in 11 patients. The results have been compared with clinical examination, CT and ultrasound scans, surgical findings and serum CA125 concentrations. Macroscopic disease was present at the time of scanning in 11 patients (less than 2 cm, eight patients, greater than 2 cm, three patients). Clinical examination and ultrasound were positive in three, CT scanning in four, immunoscintography in seven and serum CA125 in eight patients. This pilot study suggest that serum CA125 estimation is the most sensitive indicator of disease activity. However, immunoscintigraphy using this agent may localize residual disease when clinical examination and other radiological investigations fail.

Ovarian carcinoma. Advances in diagnosis, staging, and treatment

While major strides have occurred in the field of oncology and tumor biology, the basic problems of tumor heterogeneity, and mutational resistance to therapy continue to thwart progress in the diagnosis and treatment of patients with ovarian carcinoma. It is hoped ongoing clinical research using the above modalities will unfold ways to circumvent these and other major obstacles to the early diagnosis and treatment of patients with ovarian malignancies.

The impact of computed tomography and ultrasonography on the management of patients with carcinoma of the ovary

We have carried out a prospective study on the impact of computed tomography (CT) and ultrasonography (US) on the management of patients with carcinoma of the ovary. Seventy-eight CT and 88 US scans were performed on 94 patients. Clinicians decided patient management prospectively at the time the CT and/or US was ordered. Clinical assessment differed from the result obtained by CT or US in 45% of cases (35/78 and 40/88, respectively). CT and US altered patient management in only a minority of cases (14/78, 18% and 9/88, 10% respectively). Even when the scan and clinical assessments differed, management was only altered on 14/35 (40%) occasions after CT and on 9/40 (23%) occasions after US, a difference which was not significant. In patients with clinically undetectable disease, management was altered by CT on 17% of occasions and by US on 10%. We conclude that in patients with carcinoma of the ovary CT and US alters patient management in a minority of cases. In view of current financial restrictions in health care, clinicians should be more selective in the use of these imaging techniques. Furthermore, we recommend that similar prospective studies are performed for other clinical situations.

Comparison of abdominopelvic computed tomography results and findings at second-look laparotomy in ovarian carcinoma patients

In 35 women with epithelial carcinoma of the ovary, the results of restaging laparotomy were compared with the preoperative abdominopelvic computed tomography (CT) findings to evaluate the accuracy of CT for determining tumor status. In the 36 studies performed, enhanced CT scans at 10-mm to 15-mm intervals had a sensitivity of 84% and a specificity of 88%; in addition, there was 86% agreement between the CT and surgical findings. These results suggest that although CT is not accurate enough to completely replace the restaging laparotomy, its high accuracy in determining residual disease after treatment is helpful for patient management.

CA 125 as a tumour marker in epithelial ovarian cancer

CA 125, a high molecular weight glycoprotein, was measured in sera from patients with epithelial ovarian cancer, patients with benign gynaecological disease and in patients with non-ovarian adenocarcinomas. High levels (greater than 35 U/ml) were found in 48/50 patients with active ovarian cancer but in only 3/26 patients who had an ovarian cancer previously diagnosed but who were apparently disease free. 6/23 patients with non-ovarian adenocarcinomas as well as 4/18 patients with benign gynaecological disease also had elevated levels. CA 125 levels were higher in serious than non-serous ovarian cancers and tended to increase with increasing stage. In all of 19 patients with ovarian cancer who responded to treatment CA 125 levels fell while 17/20 with progressive disease showed a rise. In 7/8 patients, serial determination of CA 125 showed a rise before the clinical detection of recurrence, the median lead-time being 3.5 months. We conclude that CA 125 is an excellent marker in the management of patients with epithelial ovarian cancers.

Tumor thrombosis of the inferior vena cava due to retroperitoneal germ cell tumor

Three patients (2 males and 1 female), aged 17-28 years, with tumor thrombosis of the inferior vena cava due to retroperitoneal germ cell tumor are reported. Diagnostic and therapeutic implications of this condition are discussed.

CT findings in metastatic ovarian tumors from gastrointestinal tract neoplasms (Krukenberg tumors)

The computed tomographic (CT) findings are reviewed in 7 patients with metastatic ovarian tumors from gastrointestinal tract neoplasms (Krukenberg tumors). All patients presented mixed ovarian masses. In 6 cases the masses were mainly cystic, with internal septa and focal or uniform enlargement of the cyst wall. In the seventh patient the ovarian mass appeared on the CT as mainly solid. The size of the neoplasm varied between 5 and 46 cm. Ascites was only seen in 1 case and in another the existence of a primary tumor in the sigmoid colon was demonstrated. In our cases the CT signs of ovarian metastasis were indistinguishable from primary tumors of the ovary.

The use and abuse of imaging in gynecologic cancer

The radiologic detection in staging of gynecologic malignancies comprises a variety of noninvasive and invasive procedures. In the last few years, the emergence of the cross-sectional imaging techniques such as ultrasonography (US), computerized tomography (CT), and more recently, magnetic resonance imaging (MRI) have enabled the radiologist to determine more accurately the entire degree and extent of pathologic processes both within the pelvis and spread of disease outside the pelvis. The radiologist has also become more involved in invasive procedures such as percutaneous biopsies, aspirations of fluid collections, and transcatheter intraarterial infusion and occlusions. Although the newer imaging modalities will be emphasized, an attempt will be made to point out both their strengths and weaknesses relative to the older modalities. The discussion will concentrate on ovarian and cervical cancers while the other cancers of the female genital tract will be superficially discussed. The thrust of the presentation will emphasize the workup of gynecologic patients, that the workup may be quick, thorough, and as practical as possible.

Pitfalls in interpretation of computed tomography prior to second-look laparotomy in patients with ovarian cancer

Fifty-seven patients with ovarian cancer were assessed with computed tomography (CT) prior to undergoing second-look laparotomy. All patients were clinically free of disease following chemotherapy. Patients were scanned from the top of the liver to the symphysis pubis using oral, rectal and intravenous contrast medium. Tumour was correctly identified on CT scan in nine of 25 patients who had visible evidence of cancer at laparotomy. However, in the remaining 16 patients peritoneal studding was present and was not detected. Tumours smaller than 1.5 cm in size were not found by CT scanning. Computed tomography showed abnormality in eight of 32 patients subsequently found to be free of disease. Fine-needle aspiration cytology, bolus contrast injection and repeat scanning with additional oral contrast medium could have assisted in these circumstances. As persistent disease is by definition, a contraindication to second-look laparotomy, aggressive pre-operative assessment will spare some patients unnecessary surgery. However, CT cannot detect the small nodules often present in ovarian cancer, and thus, normal scans cannot replace surgical restaging.

Use of indium-111-labeled OC-125 monoclonal antibody in the detection of ovarian cancer

This is a preliminary study to evaluate the utility of using the monoclonal antibody (CO-125) labeled with indium-111 to image recurrences of ovarian cancer. This technique has been investigated in 23 patients with ovarian cancer and the results have been compared with blood OC-125 levels, CT scans, and findings at second-look surgery. Following infusion of 1 mg of F(ab')2 fragments (1-2 mCi 111In), quantitative SPECT and planar imaging was obtained daily for 72 hr along with analysis of serum. The nuclear medicine scans of the tumor site recurrences were technically excellent. When compared to second-look laparotomy, there were 2 true negatives, 2 false positives, 14 true positives, and 2 false negatives by nuclear imaging. CT scans correlated less well with surgery, but serum OC-125 levels correlate more closely with nuclear scans and second-look surgery. Those with multiple small metastatic implants showed a pattern of diffuse uptake which increased with time, whereas those with nodal or larger recurrences showed a more focal uptake. The combination of favorable biodistribution and positive images, especially in patients with normal antigen levels and negative CT scans, suggests a role for OC-125 monoclonal antibody imaging in their clinical management. However, further investigation is needed to determine whether nuclear scans can replace second-look surgery. If it can show that enough 111In-labeled antibody accumulates in the tumor site to justify radioimmunotherapy, then 90Y (a pure beta emitter) could be exchanged for 111In. This is potentially a method of radioimmunotherapy for recurrent ovarian carcinoma.

Correlation of abdominal CT imaging with autopsy findings in patients with malignant tumors

The value of abdominal computed tomography (CT) in diagnosing localized involvement of liver, pancreas, adrenals, and lymph nodes was evaluated in 117 patients with suspected or known malignant tumors by correlation with autopsy findings. Sensitivity, specificity, and accuracy of CT for localized liver disease was calculated to be 80% (84%), 96% (97%), and 90% (92%); for pancreatic tumors: 81% (86%), 98% (100%), and 95% (97%); for adrenal tumors: 65% (92%), 100% (100%), and 92% (98%); and for lymph node enlargement 75 (88%), 97% (98%), and 87% (94%), respectively. Results of routine evaluation could be improved, especially in the adrenal region, when scans were reevaluated by highly experienced examiners (results given in parenthesis). Computed tomography is a highly valuable diagnostic tool in the primary diagnosis and in the follow-up of tumor patients. The high costs are offset by a reduction in invasive procedures and a shortened hospital stay.

A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer

A new method with a low pH step to dissociate serum complexes has been developed to measure serum levels of antigens associated with ovarian cancer. The antigens are detected by monoclonal antibodies HMFG1 and HMFG2 and have been compared to an existing ovarian cancer associated antigen detected by the antibody CA125. Elevated HMFG1 was found in 56%, and elevated HMFG2 in 65% of 924 sera from 85 patients with ovarian cancer. CA125 was elevated in 85% of these sera. When the three markers were used in conjunction, 95% of sera from patients with ovarian cancer were positive--compared with 7% in sera from healthy control subjects. Therefore, the combination of HMFG1, HMFG2 and CA125 increases the diagnostic accuracy. If all three markers are normal in a patient previously treated for ovarian cancer then no further positive information regarding disease status can be obtained by ultrasound and CT scanning.

Computed tomography in evaluation of gynecologic malignancies: a retrospective analysis

The results of preoperative computed tomography and operative findings were assessed retrospectively in 52 patients with cervical, uterine, and ovarian neoplasms. Overall sensitivity and specificity for all disease states was 57% and 79%, respectively. Overall diagnostic accuracy was 69%. The use of computed tomography was felt to be helpful in evaluation of lymphadenopathy due to cervical cancer and in patients with suspected ovarian neoplasms. In uterine neoplasms, however, computed tomography did not add useful information.

Computed tomography of abdominal carcinoid tumour

Ten patients with pathologically proven abdominal carcinoid tumour were assessed by computed tomography (CT). Post-mortem examination correlation was obtained in two cases. Computed tomography demonstrated the extent of intra-abdominal tumour well and is, therefore, a useful staging technique for patients being treated with adjuvant therapy. The appearances of metastatic carcinoid within the mesentery on CT are characteristic and can enable a pre-operative diagnosis to be made.

Computed tomography prior to surgery for ovarian carcinoma

The value of investigation of patients with ovarian carcinoma by preoperative computed tomography scan was evaluated in all the patients operated on during the last 2 years; 22 patients were included in this study and evaluated. In 11 patients the scan was performed prior to the primary surgery and in the other 11 patients before second look following chemotherapy. CT scan was found to be highly sensitive in detecting ascites, pelvic wall extension and spread or involvement of the uterus. Peritoneal and omental spread was detected in only half of the patients before primary surgery. Prior to second look operation CT scan was effective in excluding liver metastasis, ascites, paraaortic lymph node enlargement, pelvic wall extension and pelvic residual tumour. Generally, CT scan failed to detect peritoneal and omental spread. It is an important tool for preoperative evaluation of the extension of the disease and planning of surgery, but still, the final staging deserves explorative laparotomy.

A prospective trial of computed tomography in the staging of ovarian malignancy

Thirty patients, thought clinically to have ovarian tumours, were studied prospectively by pre-operative computed tomographic (CT) scans of the abdomen and pelvis. In six patients (20%) small metastases in mesentery, omentum and on subdiaphragmatic peritoneum were not detected by the scans. CT did not improve the accuracy of staging or assist the surgeons by drawing their attention to disease which they might otherwise have missed. Although CT gives an elegant demonstration of anatomy, it is not an alternative to extended laparotomy in patients with ovarian tumours.

Intra-abdominal ovarian pathology: a potential pitfall in CT diagnoses

The ability of CT to detect abdominal and pelvic masses is well accepted. The location of the mass and its CT characteristics aid in the formulation of a diagnosis. Awareness that ovarian pathology can present as intra-abdominal rather than the usual pelvic mass will diminish misdiagnosis.

Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker

Serum CA 125, quantified by an immunoradiometric assay employing the monoclonal antibody 0C125 was found to be elevated in 48/58 (83%) of patients with established ovarian cancer. All histological types of carcinoma were antigen positive and there was a positive correlation between the frequency and level of serum CA125 and body burden of tumour. Twenty patients undergoing chemotherapy had serial CA125 estimations following a prospective protocol. Variation in CA125 level reflected disease progression or regression in 21/23 instances. Three of 9 patients tested showed an acute elevation of CA125 in the first week following chemotherapy and this effect predicted a good response to treatment. The natural half-life of CA125 in serum was estimated at approximately 4.8 days, sufficiently short to allow changes in tumour volume to be rapidly reflected by a change in circulating antigen level. Although none of 15 patients with non-Hodgkin lymphoma demonstrated antigen levels outside the normal range, 11/27 patients with non-ovarian adenocarcinoma showed elevated CA125 levels, a specificity of 58% for this latter group. The value of CA125 in the management of ovarian malignancy is discussed.

Correlation of ultrasound and pathologic findings in patients with epithelial carcinoma of the ovary

The findings from preoperative diagnostic ultrasound were compared with operative and pathologic findings in patients with ovarian cancer. Twenty laparotomies were diagnostic second-look procedures and 21 were therapeutic procedures in patients with clinically evident disease. Ultrasound was more reliable in patients with clinically suspected disease, but a site by site analysis demonstrated it is insensitive for detecting prevertebral adenopathy less than 3 cm in size, thin, 1.5 cm omental plaques, 5 cm or smaller lesions involving the mesentery or bowel and peritoneal masses 2 cm or less in size. Ultrasound was most sensitive in the detection of ascites.

Computed tomography of ovarian carcinoma

Forty-seven patients with ovarian carcinoma were examined with computed tomography (CT). Fourteen were evaluated before laparotomy (group I), 25 following surgical treatment (group II), and 8 were followed by CT in the course, or following chemotherapy with or without radiation therapy (group III). CT provided accurate estimates of the size, shape and structure of the ovarian tumor in 8 patients in group I and contributed to diagnosis in 3 others. Primary ovarian tumors were incorrectly diagnosed in 3 cases. CT examination was valuable for detection of metastases in the mesenterium, omentum, peritoneum, abdominal organs and lymph nodes. The detection of small (1 cm diameter) metastatic implants on the peritoneal surface, omentum and liver capsule was facilitated by the presence of ascites. CT proved useful for patient follow-up, either after surgical treatment or when chemotherapy with or without radiation therapy was used.

Computed tomography of intraperitoneal malignancy

A review of 205 abdominal computed tomographic (CT) scans in 83 patients with gastric or ovarian neoplasms was performed in order to assess their contribution to management. Assessment of scan accuracy was based on results of invasive procedures, clinical data, and double-blind re-reporting. Scans appeared to be of greater value in patients with ovarian rather than gastric neoplasms (p less than 0.001), and in patients undergoing clinically-indicated rather than routine scans (p less than 0.001). No clinical benefit accrued from the use of pre-treatment scans. Overall accuracy of scanning was judged to be significantly greater for the ovarian than the gastric group (p less than 0.001), while concordance of scan reports with re-reporting was also greater in the ovarian group (p less than 0.001). The data indicate the inherent limitations of the CT scan and the high degree of subjectivity in its interpretation, particularly when used in the follow-up of patients with known or suspected recurrent gastric cancer. CT scanning remains a potentially useful adjunct to clinical assessment of patients with intraperitoneal malignancy, but should not be regarded as obviating the need for clinical judgement in management decisions.